TDP-43 dysregulation and neuromuscular junction disruption in amyotrophic lateral sclerosis

被引:0
作者
Sarah Lépine
Maria José Castellanos-Montiel
Thomas Martin Durcan
机构
[1] McGill University,The Neuro’s Early Drug Discovery Unit (EDDU), Department of Neurology and Neurosurgery, Montreal Neurological Institute
[2] McGill University,Hospital
来源
Translational Neurodegeneration | / 11卷
关键词
Amyotrophic lateral sclerosis; Denervation; Neuromuscular junction; TDP-43; Dying-back; Dying-forward;
D O I
暂无
中图分类号
学科分类号
摘要
Amyotrophic lateral sclerosis (ALS) is a disease characterized by upper and lower motor neuron (MN) loss with a signature feature of cytoplasmic aggregates containing TDP-43, which are detected in nearly all patients. Mutations in the gene that encodes TDP-43 (TARBDP) are known to result in both familial and sporadic ALS. In ALS, disruption of neuromuscular junctions (NMJs) constitutes a critical event in disease pathogenesis, leading to denervation atrophy, motor impairments and disability. Morphological defects and impaired synaptic transmission at NMJs have been reported in several TDP-43 animal models and in vitro, linking TDP-43 dysregulation to the loss of NMJ integrity in ALS. Through the lens of the dying-back and dying-forward hypotheses of ALS, this review discusses the roles of TDP-43 related to synaptic function, with a focus on the potential molecular mechanisms occurring within MNs, skeletal muscles and glial cells that may contribute to NMJ disruption in ALS.
引用
收藏
相关论文
共 1400 条
[1]  
Charcot J-M(1869)Deux cas d’atrophie musculaire progressive avec lésions de la substance grise et des faiseaux antéro-latéraux de la moelle épinière Arch Physiol Norm Pathol. 2 744-760
[2]  
Joffroy A(2001)The course of the terminal phase in patients with amyotrophic lateral sclerosis J Neurol 248 612-6
[3]  
Neudert C(2003)Prognosis in amyotrophic lateral sclerosis: a population-based study Neurology 60 813-9
[4]  
Oliver D(1994)A controlled trial of riluzole in amyotrophic lateral sclerosis N Engl J Med 330 585-91
[5]  
Wasner M(1996)Dose-ranging study of riluzole in amyotrophic lateral sclerosis Lancet 347 1425-31
[6]  
Borasio GD(2017)Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis Degener Neurol Neuromuscul Dis 7 61-70
[7]  
del Aguila MA(2017)Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial Lancet Neurol 16 505-12
[8]  
Longstreth WT(2016)A long-term safety and efficacy extension study of patients diagnosed with amyotrophic lateral sclerosis (ALS) and treated with edaravone (MCI-186) Neurology 86 Suppl. P3.192-30
[9]  
McGuire V(2020)Trial of sodium phenylbutyrate–taurursodiol for amyotrophic lateral sclerosis N Engl J Med 383 919-9
[10]  
Koepsell TD(2020)Long-term treatment with AMX0035 in the open-label extension of CENTAUR, a randomized controlled trial in individuals with amyotrophic lateral sclerosis Muscle Nerve 62 105-72